What question did this study set out to answer?

To evaluate the long-term overall survival outcomes and deep response benefits of adding daratumumab to standard CyBorD chemotherapy in patients with newly diagnosed systemic AL amyloidosis.

August 30, 2026BloodOpen Access

Daratumumab in AL amyloidosis: survival, cardiac CR, and beyond

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: previously untreated systemic immunoglobulin light chain (AL) amyloidosis. Intervention: daratumumab-CyBorD vs. CyBorD alone. Primary outcome: overall survival (OS).

Q: What does this research mean for the field?

Daratumumab-CyBorD provides an overall survival advantage over CyBorD alone in previously untreated AL amyloidosis, with an absolute improvement of ~12% at 5 years despite substantial crossover. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Why the study?

Does daratumumab-CyBorD improve overall survival in previously untreated systemic AL amyloidosis compared to CyBorD alone?

Population

Patients with previously untreated systemic immunoglobulin light chain (AL) amyloidosis

Comparison

Daratumumab-CyBorD vs CyBorD alone

Design

Editorial

Follow-up

5 years

Key result

Daratumumab-CyBorD provided an overall survival advantage over CyBorD alone in previously untreated AL amyloidosis, with an absolute improvement of ~12% at 5 years despite substantial crossover.

Authors

RCRajshekhar Chakraborty

Discussion

Member takes

Key expert perspectives

Captured external expert commentary on this paper, strongest first. Original sources are linked where available.

DR Dr. Rajshekhar ChakrabortyHematologist

“The final analysis of the ANDROMEDA trial marks a landmark moment in AL amyloidosis: confirming that rapid and profound hematologic responses, driven by combining anti-CD38 monoclonal antibody daratumumab with CyBorD, translates into a clinically meaningful survival benefit. Daratumumab now joins melphalan and bortezomib as the third agent in AL to improve OS in a randomized trial.”

Columbia University Irving Medical CenterDr. Rajshekhar Chakraborty

DR Dr. Rajshekhar ChakrabortyHematologist

“In ANDROMEDA, the cardiac CR rate was approximately threefold higher with daratumumab-CyBorD than CyBorD alone (40.7% vs 13.7%), and patients achieving cardiac CR demonstrated a near-flat survival curve with 5-year OS exceeding 95%.”

Columbia University Irving Medical CenterDr. Rajshekhar Chakraborty

DR Dr. Rajshekhar ChakrabortyHematologist

“Cardiac treatment-emergent adverse events (TEAEs) were substantial: 9.3% of patients experienced cardiac failure and 11.4% of patients in the daratumumab-CyBorD arm died due to adverse events within 30 days of the last study treatment, although most were attributed to baseline cardiac involvement rather than treatment.”

Columbia University Irving Medical CenterDr. Rajshekhar Chakraborty

Overview

May support daratumumab-CyBorD upfront in AL amyloidosis; confirms deep responses translating to OS despite crossover.

Key Points

To evaluate the long-term overall survival outcomes and deep response benefits of adding daratumumab to standard CyBorD chemotherapy in patients with newly diagnosed systemic AL amyloidosis.
Final analysis of the randomized ANDROMEDA trial comparing frontline daratumumab plus CyBorD (cyclophosphamide, bortezomib, and dexamethasone) against CyBorD alone.
Assessed previously untreated patients with systemic immunoglobulin light chain (AL) amyloidosis with long-term follow-up and tracking of subsequent crossover therapies.
Treatment with daratumumab-CyBorD established a threefold improvement in deep hematologic complete response compared with CyBorD alone.
The combination conferred a clinically meaningful overall survival advantage with an absolute improvement of ~12% at 5 years, emerging despite 71% of control arm patients receiving subsequent daratumumab-based therapy.

Structured PICO

Does daratumumab-CyBorD improve overall survival in previously untreated systemic AL amyloidosis compared to CyBorD alone?

Population

Patients with previously untreated systemic immunoglobulin light chain (AL) amyloidosis

Intervention

Daratumumab-CyBorD (cyclophosphamide, bortezomib, and dexamethasone)

Comparator

CyBorD alone (with 71% of patients crossing over to receive a daratumumab-based regimen as subsequent therapy)

Outcome

Overall survival (OS)hard clinical

Main Result

Absolute Risk Reduction: 12

Absolute Risk Reduction: 12%

The addition of daratumumab to CyBorD in previously untreated AL amyloidosis provides a clinically meaningful long-term overall survival benefit.

Cite This Study

Rajshekhar Chakraborty (2026) conducted an editorial in previously untreated systemic immunoglobulin light chain (AL) amyloidosis. daratumumab-CyBorD vs. CyBorD alone was evaluated on overall survival (OS). Daratumumab-CyBorD provided an overall survival advantage over CyBorD alone in previously untreated AL amyloidosis, with an absolute improvement of ~12% at 5 years despite substantial crossover.

synapsesocial.com/papers/6a93f00a6c1a8fb52e79c063 https://doi.org/10.1182/blood.2026034366

View Full Paper

Ask AI

Bookmark

August 30, 2026BloodOpen Access

Daratumumab in AL amyloidosis: survival, cardiac CR, and beyond

View Full Paper

Ask AI

Bookmark

Why the study?

Does daratumumab-CyBorD improve overall survival in previously untreated systemic AL amyloidosis compared to CyBorD alone?

Population

Patients with previously untreated systemic immunoglobulin light chain (AL) amyloidosis

Comparison

Daratumumab-CyBorD vs CyBorD alone

Design

Editorial

Follow-up

5 years

Key result

Daratumumab-CyBorD provided an overall survival advantage over CyBorD alone in previously untreated AL amyloidosis, with an absolute improvement of ~12% at 5 years despite substantial crossover.

Authors

RCRajshekhar Chakraborty

Discussion

Member takes

Key expert perspectives

Captured external expert commentary on this paper, strongest first. Original sources are linked where available.

DR Dr. Rajshekhar ChakrabortyHematologist

“The final analysis of the ANDROMEDA trial marks a landmark moment in AL amyloidosis: confirming that rapid and profound hematologic responses, driven by combining anti-CD38 monoclonal antibody daratumumab with CyBorD, translates into a clinically meaningful survival benefit. Daratumumab now joins melphalan and bortezomib as the third agent in AL to improve OS in a randomized trial.”

Columbia University Irving Medical CenterDr. Rajshekhar Chakraborty

DR Dr. Rajshekhar ChakrabortyHematologist

“In ANDROMEDA, the cardiac CR rate was approximately threefold higher with daratumumab-CyBorD than CyBorD alone (40.7% vs 13.7%), and patients achieving cardiac CR demonstrated a near-flat survival curve with 5-year OS exceeding 95%.”

Columbia University Irving Medical CenterDr. Rajshekhar Chakraborty

DR Dr. Rajshekhar ChakrabortyHematologist

“Cardiac treatment-emergent adverse events (TEAEs) were substantial: 9.3% of patients experienced cardiac failure and 11.4% of patients in the daratumumab-CyBorD arm died due to adverse events within 30 days of the last study treatment, although most were attributed to baseline cardiac involvement rather than treatment.”

Columbia University Irving Medical CenterDr. Rajshekhar Chakraborty

Overview

May support daratumumab-CyBorD upfront in AL amyloidosis; confirms deep responses translating to OS despite crossover.

Key Points

To evaluate the long-term overall survival outcomes and deep response benefits of adding daratumumab to standard CyBorD chemotherapy in patients with newly diagnosed systemic AL amyloidosis.
Final analysis of the randomized ANDROMEDA trial comparing frontline daratumumab plus CyBorD (cyclophosphamide, bortezomib, and dexamethasone) against CyBorD alone.
Assessed previously untreated patients with systemic immunoglobulin light chain (AL) amyloidosis with long-term follow-up and tracking of subsequent crossover therapies.
Treatment with daratumumab-CyBorD established a threefold improvement in deep hematologic complete response compared with CyBorD alone.
The combination conferred a clinically meaningful overall survival advantage with an absolute improvement of ~12% at 5 years, emerging despite 71% of control arm patients receiving subsequent daratumumab-based therapy.

Structured PICO

Does daratumumab-CyBorD improve overall survival in previously untreated systemic AL amyloidosis compared to CyBorD alone?

Population

Patients with previously untreated systemic immunoglobulin light chain (AL) amyloidosis

Intervention

Daratumumab-CyBorD (cyclophosphamide, bortezomib, and dexamethasone)

Comparator

CyBorD alone (with 71% of patients crossing over to receive a daratumumab-based regimen as subsequent therapy)

Outcome

Overall survival (OS)hard clinical

Main Result

Absolute Risk Reduction: 12

Absolute Risk Reduction: 12%

The addition of daratumumab to CyBorD in previously untreated AL amyloidosis provides a clinically meaningful long-term overall survival benefit.

Cite This Study

synapsesocial.com/papers/6a93f00a6c1a8fb52e79c063 https://doi.org/10.1182/blood.2026034366

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark